GlassScriptPhysician profile
Oren S Keiser
NPI 1548203383
$5,204.48
in general payments reported to CMS, 2019-2025
31 companies · $424 in 2025
The $424 reported for 2025 was more than what 75% of Obstetrics providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $504 · 2020: $805 · 2021: $710 · 2022: $2,030 · 2023: $512 · 2024: $219 · 2025: $424.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,070 · Education: $85.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,070.19 |
| Education | $85.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celularity INC. | $3,078.00 | 2019-2022 | |
| Medtronic, INC. | $325.26 | 2022 | |
| Myriad Women'S Health, INC. | $270.72 | 2023 | Myrisk |
| Mayne Pharma Commercial LLC | $228.79 | 2021-2025 | |
| Millicent US INC | $172.69 | 2023-2025 | Femring, Intrarosa, Femlyv |
| Astellas Pharma US INC | $110.77 | 2023-2024 | Veozah |
| Therapeuticsmd, INC. | $103.85 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $87.25 | 2020-2023 | Gardasil 9 |
| Exeltis, USA INC. | $80.40 | 2024-2025 | Slynd |
| Abbvie INC. | $73.56 | 2020-2023 | |
| Evofem Biosciences, INC. | $72.59 | 2022-2025 | Solosec, Phexx, Phexxi |
| Allergan, INC. | $69.84 | 2019-2020 | |
| Pfizer INC. | $67.61 | 2019-2021 | |
| Dysis Medical, INC. | $59.71 | 2021-2022 | |
| Organon LLC | $56.91 | 2023-2024 | Nexplanon |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $45.00 | 2025 | |
| Exact Sciences Corporation | $28.49 | 2025 | The Cologuard Plus Collection Kit |
| Amag Pharmaceuticals, INC. | $27.95 | 2019-2020 | |
| Mimedx Group, INC. | $26.85 | 2025 | |
| Avion Pharmaceuticals | $25.99 | 2022-2023 | Balcoltra |
| Ethicon US, LLC | $22.50 | 2020 | |
| Meditrina | $22.40 | 2025 | |
| Coopersurgical, INC. | $21.31 | 2025 | Paragard T 380a |
| Mission Pharmacal Company | $21.22 | 2020 | |
| Sage Therapeutics, LLC | $18.97 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.76 | 2025 | Xifaxan |
| Sumitomo Pharma America, INC. | $15.45 | 2024 | Myfembree |
| Vertical Pharmaceuticals, LLC | $13.81 | 2019 | |
| Medicem INC. | $13.57 | 2021 | |
| Horizon Therapeutics Plc | $13.13 | 2020 | |
| Duchesnay USA Incorporated | $13.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Oren Keiser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.